Andreas berheide / Shutterstock.com
The Dutch lobby to amend Directive 98/44/EC on the legal protection of biotechnological inventions will severely damage the ability of the biotech sector to innovate—and for no tangible reason, says Annemiek Verkamman of HollandBIO.
Life sciences and biotechnology are delivering treatments for an increasing number of unmet medical needs, while infectious diseases are being eradicated through innovative vaccines. Proper protection of intellectual property is a crucial factor for meeting the needs of our society in the near future.
By announcing her intention to amend Directive 98/44/EC on the legal protection of biotechnological inventions in order to benefit just a few Dutch breeders, the Dutch minister for agriculture, Sharon Dijksma, is directly leaving the 600 innovative biotech companies in the Netherlands out in the cold. Amending the biotech directive will block innovation and diminish the global position of the whole European biotech sector. What is the motivation for the change? To solve an alleged problem that is solely based on fear and fable.
Dutch life sciences sector is booming
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
HollandBIO, biotechnology, R&D, IP, patent, ILP, EPO, Annemiek Verkamman, plant breeders,